Drug Type Antibody drug conjugate (ADC) |
Synonyms Nano-doxorubicin |
Target |
Action antagonists, inhibitors |
Mechanism HER2 antagonists(Receptor protein-tyrosine kinase erbB-2 antagonists), Top II inhibitors(Topoisomerase II inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPhase 3 |
First Approval Date- |
Regulation- |
Molecular FormulaC27H29NO11 |
InChIKeyAOJJSUZBOXZQNB-TZSSRYMLSA-N |
CAS Registry23214-92-8 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Breast Cancer | Phase 3 | Germany | 01 Jul 2014 | |
Breast Cancer | Phase 3 | Spain | 01 Jul 2014 | |
Breast Cancer | Phase 3 | Czechia | 01 Jul 2014 | |
Breast Cancer | Phase 3 | Austria | 01 Jul 2014 | |
Breast Cancer | Phase 3 | Canada | 01 Jul 2014 | |
Breast Cancer | Phase 3 | France | 01 Jul 2014 | |
Breast Cancer | Phase 3 | Belgium | 01 Jul 2014 | |
Breast Cancer | Phase 3 | Italy | 01 Jul 2014 | |
Breast Cancer | Phase 3 | United States | 01 Jul 2014 | |
HER2 Positive Breast Cancer | Phase 3 | United States | 01 Jul 2014 |
Phase 1 | 69 | (zkkopxlbig) = 1 patient experienced Grade 1 cardiac failure resulting in treatment discontinuation uwkwrylqdq (iauuvrpyxb ) View more | - | 01 Aug 2015 | |||